Thus, POU6F2-AS1 plays a pivotal role in the oncogenic METTL3/POU6F2-AS1/YBX1/FASN axis to promote CRC cell lipogenesis and growth, which provides new insight into lipid accumulation in CRC and highlights, POU6F2-AS1 as a promising therapeutic target for patients with CRC. This evidence concerns the gene YBX1 and colorectal carcinoma.